The activity of cell-free supernatant of Lactobacillus crispatus M247: a promising treatment against vaginal infections

<i>Lactobacillus crispatus</i> is renowned for its antimicrobial properties, and some strains are used to treat vaginal dysbiosis, although the mechanisms underlying the antimicrobial properties remain elusive. We isolated <i>L. crispatus</i> M247 (LcM247) from a commercially available probiotic product Crispact<sup>®</sup> and tested its antimicrobial activity against selected pathobionts such as <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Staphylococcus aureus</i>, <i>Streptococcus agalactiae</i>, <i>Enterococcus faecalis</i> and <i>Candida albicans</i> using both cocultures and testing the antimicrobial activity of cell-free supernatant (CFS) obtained from the culture of the probiotic strain. Furthermore, we demonstrate that CFS antimicrobial activity is pH dependent and that it is not affected by temperature and proteinase K treatment. Proteomic analysis suggests that this activity is mediated by S-layer secreted proteins. In a series of <i>in vitro</i> infection models, we infected Henrietta Lacks' cervical eukaryotic cancer cells (HeLa) with <i>E. coli</i>, <i>S. agalactiae</i> and <i>C. albicans</i> at specific multiplicities of infection (MOIs) before the administration of LcM247, CFS, gentamicin or fluconazole alone or in combination with LcM247/CFS. We observed a slight decrease in the microbial burden following LcM247 administration, while treatment with CFS significantly reduced microbial growth compared to control and antimicrobial compounds. These results highlight the antimicrobial properties of LcM247 and its CFS and the likely mechanism of action that contributes to the eradication of common pathobionts. We show that actively replicating LcM247 is less efficient than its CFS, so the oral administration of LcM247 may result in treatment failure. Finally, the use of CFS may result in an upswing of the host <i>Lactobacillus</i> strains and promote the engraftment of <i>Lactobacillus</i> probiotic treatments.

Authors

Institutions

Publication Details

Journal
Frontiers in Cellular and Infection Microbiology
Published
2025-06-11
DOI
https://doi.org/10.3389/fcimb.2025.1586442
Citations
7
Primary Topic
Reproductive tract infections research
Type
article
Field-Weighted Citation Impact
8.28
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The activity of cell-free supernatant of Lactobacillus crispatus M247: a promising treatment against vaginal infections

Giulia Santarelli, Flavio De Maio, Andrea Urbani, Giovanni Delogu et al.
7 citations
Frontiers in Cellular and Infection Microbiology
Reproductive tract infections research
8.28
article

The activity of cell-free supernatant of Lactobacillus crispatus M247: a promising treatment against vaginal infections

Giulia Santarelli, Flavio De Maio, Andrea Urbani, Giovanni Delogu, Federica Iavarone, Maurizio Sanguinetti, Michela Cicchinelli, Roberto Rosato
article en
7 citations

Abstract

<i>Lactobacillus crispatus</i> is renowned for its antimicrobial properties, and some strains are used to treat vaginal dysbiosis, although the mechanisms underlying the antimicrobial properties remain elusive. We isolated <i>L. crispatus</i> M247 (LcM247) from a commercially available probiotic product Crispact<sup>®</sup> and tested its antimicrobial activity against selected pathobionts such as <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Staphylococcus aureus</i>, <i>Streptococcus agalactiae</i>, <i>Enterococcus faecalis</i> and <i>Candida albicans</i> using both cocultures and testing the antimicrobial activity of cell-free supernatant (CFS) obtained from the culture of the probiotic strain. Furthermore, we demonstrate that CFS antimicrobial activity is pH dependent and that it is not affected by temperature and proteinase K treatment. Proteomic analysis suggests that this activity is mediated by S-layer secreted proteins. In a series of <i>in vitro</i> infection models, we infected Henrietta Lacks' cervical eukaryotic cancer cells (HeLa) with <i>E. coli</i>, <i>S. agalactiae</i> and <i>C. albicans</i> at specific multiplicities of infection (MOIs) before the administration of LcM247, CFS, gentamicin or fluconazole alone or in combination with LcM247/CFS. We observed a slight decrease in the microbial burden following LcM247 administration, while treatment with CFS significantly reduced microbial growth compared to control and antimicrobial compounds. These results highlight the antimicrobial properties of LcM247 and its CFS and the likely mechanism of action that contributes to the eradication of common pathobionts. We show that actively replicating LcM247 is less efficient than its CFS, so the oral administration of LcM247 may result in treatment failure. Finally, the use of CFS may result in an upswing of the host <i>Lactobacillus</i> strains and promote the engraftment of <i>Lactobacillus</i> probiotic treatments.

Frontiers in Cellular and Infection MicrobiologyVol. 15
Università Cattolica del Sacro Cuore (IT), Agostino Gemelli University Polyclinic (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Openalex Percentile: Top 2%
Reproductive tract infections research
8.28
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.